Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research

Although re-sequencing of gene panels and mRNA expression profiling are now firmly established in clinical laboratories, in-depth proteome analysis has remained a niche technology, better suited for studying model systems rather than challenging materials such as clinical trial samples. To address this limitation, we have developed a novel and optimized platform called SP3-Clinical Tissue Proteomics (SP3-CTP) for in-depth proteome profiling of practical quantities of tumour tissues, including formalin fixed and paraffin embedded (FFPE). Using single 10 μm scrolls of clinical tumour blocks, we performed in-depth quantitative analyses of individual sections from ovarian tumours covering the high-grade serous, clear cell, and endometrioid histotypes. This examination enabled the generation of a novel high-resolution proteome map of ovarian cancer histotypes from clinical tissues. Comparison of the obtained proteome data with large-scale genome and transcriptome analyses validated the observed proteome biology for previously validated hallmarks of this disease, and also identified novel protein features. A tissue microarray analysis validated cystathionine gamma-lyase (CTH) as a novel clear cell carcinoma feature with potential clinical relevance. In addition to providing a milestone in the understanding of ovarian cancer biology, these results show that in-depth proteomic analysis of clinically annotated FFPE materials can be effectively used as a biomarker discovery tool and perhaps ultimately as a diagnostic approach.

[1]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[2]  K. Rodland,et al.  Proteomics of ovarian cancer: functional insights and clinical applications , 2015, Cancer and Metastasis Reviews.

[3]  Andrew R. Jones,et al.  ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.

[4]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[5]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..

[6]  L. Walsh,et al.  Embryonic protein nodal promotes breast cancer vascularization. , 2012, Cancer research.

[7]  Eytan Ruppin,et al.  System-wide Clinical Proteomics of Breast Cancer Reveals Global Remodeling of Tissue Homeostasis. , 2016, Cell systems.

[8]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[9]  M. Mann,et al.  Absolute Proteome Analysis of Colorectal Mucosa, Adenoma, and Cancer Reveals Drastic Changes in Fatty Acid Metabolism and Plasma Membrane Transporters. , 2015, Journal of proteome research.

[10]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[11]  M. Mann,et al.  Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma , 2012, Molecular systems biology.

[12]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[13]  A. Weaver,et al.  Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance , 2013, PloS one.

[14]  L. Kruglyak,et al.  The role of regulatory variation in complex traits and disease , 2015, Nature Reviews Genetics.

[15]  E. Bruford,et al.  Update on the Kelch-like (KLHL) gene family , 2013, Human Genomics.

[16]  William Stafford Noble,et al.  Semi-supervised learning for peptide identification from shotgun proteomics datasets , 2007, Nature Methods.

[17]  Gwendolyn M. Jang,et al.  Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. , 2015, Cell host & microbe.

[18]  H. Aburatani,et al.  Correction: Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas , 2015, PloS one.

[19]  M. Mann,et al.  Proteomic maps of breast cancer subtypes , 2016, Nature Communications.

[20]  M. Hendrix,et al.  Targeting Nodal in malignant melanoma cells , 2007, Expert opinion on therapeutic targets.

[21]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[22]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[23]  E. Marcotte,et al.  Global signatures of protein and mRNA expression levelsw , 2009 .

[24]  Peter Hoffmann,et al.  Proteomic developments in the analysis of formalin-fixed tissue. , 2015, Biochimica et biophysica acta.

[25]  C. Núñez,et al.  Effect of BSN-MST1 locus on inflammatory bowel disease and multiple sclerosis susceptibility , 2009, Genes and Immunity.

[26]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[27]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Jeroen Krijgsveld,et al.  Ultrasensitive proteome analysis using paramagnetic bead technology , 2014, Molecular systems biology.

[29]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[30]  S. Cannistra,et al.  Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.

[31]  Rui Wang Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  P. Oberoi,et al.  Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4 , 2013, Journal of Ovarian Research.

[33]  Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications , 2015, Cancer and Metastasis Reviews.

[34]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[35]  Andrew H. Thompson,et al.  Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. , 2003, Analytical chemistry.

[36]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[37]  S. Tabibzadeh,et al.  Lefty at the Crossroads of “Stemness” and Differentiative Events , 2006, Stem cells.

[38]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[39]  L. Walsh,et al.  Embryonic Morphogen Nodal Promotes Breast Cancer Growth and Progression , 2012, PloS one.

[40]  B. Balgley,et al.  Protein Extraction from Formalin-fixed, Paraffin-embedded Tissue Sections: Quality Evaluation by Mass Spectrometry , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  D. Hess,et al.  Nodal promotes invasive phenotypes via a Mitogen Activated Protein Kinase-dependent pathway , 2013, Oncogene.

[42]  M. Mann,et al.  Comparison of ultrafiltration units for proteomic and N-glycoproteomic analysis by the filter-aided sample preparation method. , 2011, Analytical biochemistry.

[43]  M. Hendrix,et al.  Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells , 2008, Proceedings of the National Academy of Sciences.

[44]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[45]  Samuel Leung,et al.  Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study , 2010, The American journal of surgical pathology.

[46]  N. Matsumura,et al.  Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction , 2015, Oncotarget.

[47]  Acknowledgements , 1992, Experimental Gerontology.

[48]  S. Murphy,et al.  Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes , 2010, Oncogene.

[49]  Matthias Mann,et al.  High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. , 2011, Journal of proteome research.

[50]  H. Tsuda,et al.  Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. , 2007, Human pathology.

[51]  R. Longuespée,et al.  Comparison of two FFPE preparation methods using label-free shotgun proteomics: Application to tissues of diverticulitis patients. , 2015, Journal of proteomics.

[52]  Tsutomu Ohta,et al.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. , 2003, The American journal of pathology.

[53]  William Stafford Noble,et al.  Improvements to the percolator algorithm for Peptide identification from shotgun proteomics data sets. , 2009, Journal of proteome research.

[54]  R. Sallam Proteomics in Cancer Biomarkers Discovery: Challenges and Applications , 2015, Disease markers.

[55]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[56]  D. Huntsman,et al.  A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary , 2009, The American journal of surgical pathology.

[57]  D. Bell,et al.  Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.

[58]  M. Beckmann,et al.  Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study , 2014, British Journal of Cancer.

[59]  Olli S Nevalainen,et al.  Using Peptide-Level Proteomics Data for Detecting Differentially Expressed Proteins. , 2015, Journal of proteome research.

[60]  Hedi Peterson,et al.  g:Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments , 2007, Nucleic Acids Res..

[61]  E. Lundberg,et al.  A global view of protein expression in human cells, tissues, and organs , 2009, Molecular systems biology.

[62]  Peter Bühlmann,et al.  Analyzing gene expression data in terms of gene sets: methodological issues , 2007, Bioinform..

[63]  Marie Joseph,et al.  Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  G. Lajoie,et al.  Mass Spectrometry–based Proteomic Analysis of the Matrix Microenvironment in Pluripotent Stem Cell Culture* , 2012, Molecular & Cellular Proteomics.

[65]  N. Karp,et al.  Addressing Accuracy and Precision Issues in iTRAQ Quantitation* , 2010, Molecular & Cellular Proteomics.

[66]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[67]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[68]  H. Nakada,et al.  Difference in mesothelin‐binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer , 2015, International journal of cancer.